Por Renan Filho · 2026-10-08**Lead**
HUNTSVILLE, Texas — The state of Texas executed Jamaal Howard on Thursday evening at the Huntsville Unit, making him the seventh inmate put to death in the state this year. The execution proceeded despite growing scrutiny over the compounded pentobarbital used in the lethal injection protocol — the same drug that was implicated in a visibly troubled execution in Tennessee in February, where the condemned inmate gasped and convulsed for several minutes before being pronounced dead.
Howard, 47, was pronounced dead at 6:22 p.m. local time. He had been convicted of capital murder for the 2008 killing of a corrections officer during a prison escape attempt. In his final statement, Howard maintained his innocence and criticized the state’s use of an untested drug supply. His legal team had filed multiple emergency appeals arguing that the batch of pentobarbital obtained by the Texas Department of Criminal Justice (TDCJ) was of unknown origin and potency, and that its use violated the Eighth Amendment’s prohibition on cruel and unusual punishment. The U.S. Supreme Court denied a stay of execution without comment earlier in the day.
**Contexto**
The drug at the center of the controversy is compounded pentobarbital, a barbiturate used by Texas and several other states as the sole agent in lethal injections. Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and are produced by specialized pharmacies that are not subject to the same manufacturing standards as commercial pharmaceutical companies. Texas has refused to disclose the identity of the compounding pharmacy that supplied the drug used in Howard’s execution, citing a state law that shields execution drug suppliers from public disclosure.
Concerns over the drug’s reliability intensified after the Tennessee execution in February, in which the inmate, Dennis McGuire, exhibited what witnesses described as “gasping, snorting, and convulsions” for nearly 10 minutes after the pentobarbital was administered. Medical experts who reviewed the execution footage said the reaction was consistent with a sub-lethal dose or a drug that had degraded or been improperly compounded. Tennessee officials later acknowledged that the batch of pentobarbital used had been stored for several months beyond its recommended expiration date.
Texas has used pentobarbital exclusively since 2012, after the state’s previous three-drug cocktail became unavailable due to a European Union ban on the export of drugs for use in executions. Since then, the state has relied on a network of compounding pharmacies to produce the drug, often operating under a veil of secrecy. According to the Death Penalty Information Center, Texas has executed 34 inmates since 2020, all using compounded pentobarbital from undisclosed sources. In at least three of those executions, witnesses reported unusual movements or prolonged time to death, though state officials have consistently maintained that the protocol is humane and effective.
Howard’s case drew additional attention because of the circumstances of his conviction. He was sentenced to death for the murder of correctional officer Susan Canfield during a failed escape from the Coffield Unit in 2008. Howard, who was already serving a life sentence for a previous murder, stabbed Canfield with a homemade weapon. His defense team argued that Howard suffered from severe mental illness and that his trial had been tainted by prosecutorial misconduct. Those claims were rejected by state and federal courts.
**Analise**
The execution of Jamaal Howard underscores a broader crisis in American capital punishment: the increasing difficulty states face in obtaining reliable execution drugs, and the legal and ethical questions that arise when they turn to unregulated compounding pharmacies. The secrecy surrounding drug sourcing has made it nearly impossible for courts or independent experts to verify the quality and potency of the drugs being used. This lack of transparency has fueled a growing number of legal challenges, with defense attorneys arguing that states are effectively conducting medical experiments on condemned inmates without their consent.
From a technological and pharmaceutical standpoint, the issue is stark. Compounded pentobarbital is not subject to FDA oversight, meaning there is no guarantee of sterility, potency, or chemical stability. Studies published in the Journal of the American Medical Association have found that compounded drugs used in executions have shown significant variability in concentration, with some batches containing as little as 60 percent of the labeled dose. In a 2023 analysis of execution drugs obtained from undisclosed sources, researchers at the University of Texas found that several samples contained impurities and degradation products that could affect the drug’s anesthetic and respiratory-depressant properties.
For Texas, the decision to proceed with Howard’s execution despite the Tennessee incident signals a calculated risk. The state has one of the busiest execution chambers in the country and has shown little willingness to pause executions while the drug supply is reviewed. Legal experts say that as long as the Supreme Court declines to intervene, states will continue to use compounded pentobarbital, even as the evidence of its unreliability mounts. The result is a patchwork of execution protocols that vary wildly in safety and transparency, with the ultimate burden falling on the condemned.
**Fontes**
- Texas Department of Criminal Justice (TDCJ) execution records and public statements. - Death Penalty Information Center (DPIC) database and reports on lethal injection drugs. - U.S. Supreme Court docket for Howard v. Texas, No. 25-6389 (2026). - Journal of the American Medical Association (JAMA), “Quality of Compounded Pentobarbital Used in U.S. Executions,” 2023. - Witness accounts and medical expert analysis of the February 2026 Tennessee execution, as reported by the Associated Press and The Tennessean. - Court filings from Howard’s legal team, including emergency appeals and expert affidavits on drug potency.